Enterococcal infective endocarditis (IE) is a severe disease which incidence has significantly increased in the last decades. It affects fragile and elder patients which would benefit from at-home treatment. The aim of the present study is to prove that the continuous infusion of ampicillin and ceftriaxone, which infusion regimen is more suitable for outpatient parenteral antimicrobial therapy programs (OPAT), is as effective and safe as the traditional intermittent infusion of both antibiotics for the treatment of patients with Enterococcus faecalis IE. The study is framed within the thematic priorities of the AES: 1) “Clinical research to reduce the risk of antimicrobial resistance”: Our proposal would avoid the use of broader spectrum antibiotics; 2) “Clinical research including population underrepresented in commercial clinical trials”: Elderly population is characterized by their comorbidities, fragility and chronic treatments which might determinate drug tolerance; 3) “Clinical research with authorized drugs in real-use conditions”: Ampicillin and ceftriaxone are authorized antibiotics which clinical indications, dosage and drug combinations differs from the authorized conditions; 4) “Clinical research with impact in the public health for the National Health Care System”: Our results could highly impact on the economic and resource burden of the National Health Care System (NHCS) caused by E. faecalis IE by reducing to hospital stays from 4-6 weeks to 2-3 weeks and hospital-driven complications. The results obtained in this study might have a considerable impact in the management of the E. faecalis IE. The opportunity of completing the antibiotic treatment in the outpatient provide the patients a significant increase in their quality of life, without prejudice to the efficacy and safety of the health care received. This modality of treatment is expected to provide numerous benefits for patients, global health, and the NHCS.
Enterococcus faecalis
infective endocarditis
OPAT
outpatient parenteral antibiotic therapy
ampicillin
ceftriaxone
double ß-lactam therapy
continuous infusion.
Acción Estratégica en Salud (AES)
01/01/2024 - 31/12/2027
LUIS FERNANDO LOPEZ CORTES
FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA (FISEVI)
INSTITUTO DE BIOMEDICINA DE SEVILLA - IBIS
ANDALUCIA
SEVILLA
342,619 €